Trelagliptin is used for the treatment of type 2 diabetes. It is a pharmaceutical drug.Reference standards of Trelagliptin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Trelagliptin
Catalogue No.:PA 73 11000
CAS :
Molecular Formula : C18H20FN5O2
Molecular Weight : 357.39
1-Methylbarbituric Acid
Catalogue No.:PA 73 11510
Molecular Formula : C5H6N2O3
Molecular Weight : 142.11
2,2'-((6-Chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidine-1,5(2H)-diyl)bis(methylene))bis(4-fluorobenzonitrile)
Catalogue No.:PA 73 11520
Molecular Formula : C21H13ClF2N4O2
Molecular Weight : 426.81
(R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzamide
Catalogue No.:PA 73 11530
Molecular Formula : C18H22FN5O3
Molecular Weight : 375.4
(R)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzoic Acid
Catalogue No.:PA 73 11540
Molecular Formula : C18H21FN4O4
Molecular Weight : 376.39
(S)-2-((6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
Catalogue No.:PA 73 11550
(R)-4-Fluoro-2-((3-methyl-2,4-dioxo-6-(piperidin-3-ylamino)-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile
Catalogue No.:PA 73 11560
(R)-2-((6-(3-((3-(2-Cyano-5-fluorobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
Catalogue No.:PA 73 11570
Molecular Formula : C31H28F2N8O4
Molecular Weight : 614.61
(R)-4-((1-(3-(2-Cyano-5-fluorobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)piperidin-3-yl)amino)-4-oxobutanoic Acid
Catalogue No.:PA 73 11580
Molecular Formula : C22H24FN5O5
Molecular Weight : 457.46
2-((6-Chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
Catalogue No.:PA 73 0111000
Molecular Formula : C13H9ClFN3O2
Molecular Weight : 293.68
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
